CN116672430A - 一种抗衰老镇静安神组合物及其应用 - Google Patents
一种抗衰老镇静安神组合物及其应用 Download PDFInfo
- Publication number
- CN116672430A CN116672430A CN202310583346.8A CN202310583346A CN116672430A CN 116672430 A CN116672430 A CN 116672430A CN 202310583346 A CN202310583346 A CN 202310583346A CN 116672430 A CN116672430 A CN 116672430A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- aging
- gaba
- theanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 16
- 230000002936 tranquilizing effect Effects 0.000 title claims abstract description 15
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 26
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 15
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940026510 theanine Drugs 0.000 claims abstract description 13
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 claims abstract description 12
- 241000157862 Dicamptodontidae Species 0.000 claims abstract description 12
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 claims abstract description 12
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 12
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 230000032683 aging Effects 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 230000001624 sedative effect Effects 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000000932 sedative agent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 230000036772 blood pressure Effects 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 9
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 8
- 206010022437 insomnia Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011049 filling Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003326 hypnotic agent Substances 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- XDIYNQZUNSSENW-KHYZTKRTSA-N (2r,3s,4s,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-KHYZTKRTSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供了一种抗衰老镇静安神组合物及其应用，所述组合物至少包括以下重量份数的有效成分：娃娃鱼低聚糖肽8‑12份、神经酸8‑12份、GABA8‑12份、茶氨酸8‑12份。本发明的组合物在应用于保健品时，其依赖性低、毒副作用小、安全性高、疗效好。组合物中娃娃鱼低聚糖肽、神经酸、GABA协同作用能够增强抗衰老的药理作用，GABA、茶氨酸协同作用能够增强镇静安神、降血压作用，本发明的组合物在用于制备治疗失眠、抗衰老保健品或相关的药物中提供了有效的基础。
Description
技术领域
本发明属于保健品技术领域，具体涉及一种抗衰老镇静安神组合物及其应用。
背景技术
随着人民生活水平的不断提高，抗氧化剂的使用率越来越高，市场上抗氧化剂和抗衰老剂类药物品种繁多，但主要集中在化学合成药方面，短期治疗效果显著，但长时间的使用会引起人体及动物体内生理代谢的紊乱，降低抗氧化酶的活性，增强脂质过氧化水平，从而引起脏器病变，加速衰老。健康的动物为了避免细胞和组织损伤，有着一套完整的自我防御系统，但是随着动物机体的生长发育，体内的器官逐渐老化，细胞清除活性氧的能力下降，身体防御能力也随着下降，所以自我防御系统对动物的生理活动非常重要。
虽然，人们生活水平有所提高，但伴随而来的失眠也成了很多人困扰的问题，失眠是指以经常不能获得正常睡眠为特征的一种常见疾病。轻者入睡困难，或入睡后易被惊醒，醒后不能再入睡；严重者可整夜不能入睡，常伴有头痛、头晕、健忘等。目前西医临床治疗失眠的重要方法之一是服用安眠药，但长期服用安眠药物会对患者产生明显的不良反应。如何能开发出一种具有抗衰老且能镇静安神有利于缓解失眠的组合物成为了目前需要解决的一大问题。
发明内容
为了解决现有技术的不足，本发明提供了一种抗衰老镇静安神组合物及其应用。
本发明的目的通过以下技术方案来实现：
一种抗衰老镇静安神组合物，所述组合物至少包括以下重量份数的有效成分：娃娃鱼低聚糖肽8-12份、神经酸8-12份、GABA8-12份、茶氨酸8-12份。
优选地，所述组合物按重量份数计包括：娃娃鱼低聚糖肽9-11份、神经酸9-11份、GABA10份、茶氨酸10份。
优选地，所述组合物按重量份数计包括：娃娃鱼低聚糖肽10份、神经酸10份、GABA10份、茶氨酸10份。
优选地，一种以上任意一所述的抗衰老镇静安神组合物的应用。
优选地，可以应用于制备成抗衰老镇静安神的保健品。
优选地，所述保健品的剂型为且不限于为片剂、胶囊、颗粒剂、口服液、冻干粉。
本发明的有益效果体现在：本发明的组合物在应用于保健品时，其依赖性低、毒副作用小、安全性高、疗效好。组合物中娃娃鱼低聚糖肽、神经酸、GABA协同作用能够增强抗衰老的药理作用，GABA、茶氨酸协同作用能够增强镇静安神、降血压作用，本发明的组合物在用于制备治疗失眠、抗衰老保健品或相关的药物中提供了有效的基础。
实施方式
本发明揭示了一种抗衰老镇静安神组合物，所述组合物至少包括以下重量份数的有效成分：娃娃鱼低聚糖肽8-12份、神经酸8-12份、GABA8-12份、茶氨酸8-12份。
本发明利用的原理在于：娃娃鱼低聚糖肽具有促进小鼠免疫功能的作用，抗氧化、抗疲劳作用，有抗紫外线能力、降血压、延缓衰老的功效。
神经酸是大脑神经组织和细胞的一种核心天然成分，是大脑细胞、视神经细胞、周围神经生长、再发育和维持所必需的营养物质，能够修复受损神经细胞，提高神经细胞的活跃性以延缓衰老。
GABA具有抗焦虑和镇静神经，促进睡眠，美容润肤，健脑益智，增进大脑活力，延缓衰老。GABA的用途很广，能作为一种抑制神经的产物，能参与体内多种代谢活动，还能调节情绪，缓解心境紧张。
茶氨酸是茶叶中特有的一种非蛋白氨基酸，具有保护神经、降血压、抗氧化、增强机体免疫、改善认知等多种生理活性作用。因其具有镇静安神的特性，茶氨酸在改善睡眠方面的研究逐渐增多。
以上所述的一种能抗衰老镇静安神作用的组合物，可以制成片剂，胶囊、颗粒、口服液和冻干粉的形式，具体方法如下：
片剂：将上述经过效果例验证的优选配方组合，充分搅拌均匀后制粒，压成片剂，包装，将包装袋或包装盒灭菌后进行包装封存。
胶囊：将上述经过效果例验证的优选配方组合，充分搅拌均匀，倒入胶囊填充模具中，灌装胶囊，抛光，分装，制得胶囊。
颗粒：将上述经过效果例验证的优选配方组合，充分搅拌均匀，使用浓度为50％(V/V)的乙醇作为粘合剂，制成软材，将上述软材制成颗粒，然后整粒，分装，制得颗粒剂。
口服液：将上述经过效果例验证的优选配方组合，充分混合均匀，经灌装灭菌后制成口服液。
冻干粉：将上述经过效果例验证的优选配方组合，充分搅拌均匀，灭菌后灌装经冻干制成冻干粉。
为更好的理解本发明，以下通过具体的实施例进行阐述。
本发明的组合物能起抗衰老、镇静安神、降血压作用，以下以优选的其有效成分由以下重量份数的原料制成：娃娃鱼低聚糖肽10份、神经酸10份、GABA10份、茶氨酸10份。
采用实施例1的配方制成实验药，进行动物实验：
选择健康雄性小鼠50只，按7.8 g/kg灌胃，每日两次，持续30天，未出现毒副反应。
动物实验及分组：选择健康雄性小鼠40只，适应环境一周后，将建模成功的小鼠随机分为正常对照组、衰老模型组、本发明组合物干预组和阳性(维生素E 170 mg/kg)处理组。每组10只小鼠。
模型制备：用低糖低脂饲料适应性喂养小鼠15 d，以剂量为500 mg/kg颈部皮下注射D-半乳糖(D-galactose)溶液构建小鼠亚急性衰老模型。
方法：连续灌胃给药28 d，研究本发明组合物对衰老小鼠体重及动物脏器指数、血清中超氧化物歧化酶(SOD)、过氧化氢酶(CAT)和谷胱甘肽过氧化物酶(GSH-Px)的活力变化以及丙二醛(MDA)的含量变化。
实验结果：经过测定，本发明组合物干预组对其心脏和脾脏指数、血清中的SOD、CAT和GSH-Px活力均高于模型组，差异具有统计学意义（P<0.05）；血清中的MDA含量均低于模型组，对衰老小鼠具有缓解体重下降的作用，差异具有统计学意义（P<0.05）。结果表明，本发明组合物干预组均能提高衰老小鼠的抗氧化和抗衰老作用。
1.病例选择收治门诊患者60例，患者年龄在30-60岁，临床表现：入睡困难、睡眠质量下降和睡眠时间减少，记忆力、注意力下降。部分患高血压患者。
2.治疗方法
服用本发明实施例制备的组合物，每次服用1剂，每天早、晚各服1次，20天为一个疗程，连续服用3个疗程。
疗效评定标准
显效：失眠症状消失，身体恢复正常，观察半年后无复发，血压明显降低；
好转：失眠症状明显好转，身体素质明显恢复；
无效：失眠症状无改善，高血压达不到好转标准者。
4.治疗结果
用本发明药物治疗失眠患者60例，结果显效42例，好转13例，无效5例，总有效率为92.0％，服药过程未观察到过敏及其它不良反应。
用本发明药物治疗高血压患者20例，血压明显降低17例，3例血压起伏不大，好转有效率为85%，服药过程未观察到过敏及其它不良反应。
结果显示，本发明所述的组合物，功效显著，镇静安神疗效明显，安全性好，服用方便。
且以上实施例仅用以说明本发明的技术方案，而非对其限制；尽管参照前述实施例对本发明进行了详细的说明，本领域的普通技术人员应当理解：其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分技术特征进行等同替换；而这些修改或者替换，并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。
Claims (6)
1.一种抗衰老镇静安神组合物，其特征在于：所述组合物至少包括以下重量份数的有效成分：娃娃鱼低聚糖肽8-12份、神经酸8-12份、GABA8-12份、茶氨酸8-12份。
2.如权利要求1所述的一种抗衰老镇静安神组合物，其特征在于：所述组合物按重量份数计包括：娃娃鱼低聚糖肽9-11份、神经酸9-11份、GABA10份、茶氨酸10份。
3.如权利要求2所述的一种抗衰老镇静安神组合物，其特征在于：所述组合物按重量份数计包括：娃娃鱼低聚糖肽10份、神经酸10份、GABA10份、茶氨酸10份。
4.一种如权利要求1-3中任意一所述的抗衰老镇静安神组合物的应用。
5.如权利要求4所述的应用，其特征在于：可以应用于制备成抗衰老镇静安神的保健品。
6.如权利要求5所述的应用，其特征在于：所述保健品的剂型为且不限于为片剂、胶囊、颗粒剂、口服液、冻干粉。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310583346.8A CN116672430A (zh) | 2023-05-23 | 2023-05-23 | 一种抗衰老镇静安神组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310583346.8A CN116672430A (zh) | 2023-05-23 | 2023-05-23 | 一种抗衰老镇静安神组合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116672430A true CN116672430A (zh) | 2023-09-01 |
Family
ID=87790020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310583346.8A Withdrawn CN116672430A (zh) | 2023-05-23 | 2023-05-23 | 一种抗衰老镇静安神组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116672430A (zh) |
-
2023
- 2023-05-23 CN CN202310583346.8A patent/CN116672430A/zh not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3530277A1 (en) | Chinese medicine healthcare preparations for slimming and weight loss | |
| CN111888464A (zh) | 一种具有抗衰老和提高免疫力功能的保健组合物 | |
| CN102100273A (zh) | 三高平衡茶及其制备方法 | |
| CN109820905A (zh) | 一种治疗失眠的药物组合物及其应用 | |
| CN110897029A (zh) | 一种动植物多肽压片糖果及其制备方法 | |
| JPWO2015015816A1 (ja) | 繊維芽細胞賦活剤 | |
| CN112971151A (zh) | 一种具有提高免疫力的人参核桃肽组合物及其制备方法 | |
| CN116076710A (zh) | 一种具有抗衰美白功能的玫瑰本草酵素及其制备方法和应用 | |
| CN116672430A (zh) | 一种抗衰老镇静安神组合物及其应用 | |
| CN100479671C (zh) | 一种复方微米松花魔芋露减肥降糖酸奶制备方法 | |
| CN110075280A (zh) | 一种层粘连蛋白肽复合口服剂及其制备方法 | |
| CN114432384A (zh) | 一种低氘水龙脑雾化护眼液 | |
| CN108294300A (zh) | 一种安神晚餐粉 | |
| KR101227922B1 (ko) | 파파야 퓌레 조제품 및 그 제조방법 | |
| CN112891434A (zh) | 一种提高免疫力和肾功能的药酒及其制备方法 | |
| CN105748823A (zh) | 一种美容养颜中药组合物及其制备方法 | |
| CN109078089A (zh) | 一种抗衰老、防治骨质疏松的中药组合物及其制剂 | |
| CN104984331A (zh) | 生物活性多酶修复胰腺β细胞溶液制剂及其制备方法 | |
| CN110236047A (zh) | 一种纤体美容的酵素饮品及其制备方法 | |
| JPWO2015015815A1 (ja) | 繊維芽細胞賦活剤 | |
| KR100806618B1 (ko) | 감마-폴리글루탐산을 유효성분으로 함유하는 알러지증상들의 예방, 완화 혹은 억제용 건강기능식품 | |
| CN113332314B (zh) | 一种牡蛎壳肉酶解物及其在制备治疗抑郁症的药物中的应用 | |
| CN1466995A (zh) | 一种含修饰sod的抗衰老胶囊 | |
| CN107753752A (zh) | 一种解酒护肝石斛冲剂 | |
| CN113082199A (zh) | 一种肾病药物组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20230901 |
|
| WW01 | Invention patent application withdrawn after publication |